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Introduction {#sec005}
============

Anxiety disorders are a class of psychological disturbances characterized by pervasive worry, fear, and related behavioral impairments. Collectively, they are the most prevalent form of mental illness \[[@pone.0199041.ref001]\]---affecting up to 30% of American adults at some point---and they impose a large societal burden of functional disability and mortality \[[@pone.0199041.ref002]\]. Excessive anxiety is also associated with numerous negative health outcomes, such as increased risk of coronary heart disease \[[@pone.0199041.ref003]\], impaired sleep \[[@pone.0199041.ref004]\], and alcohol and substance abuse \[[@pone.0199041.ref005]\]. Although there now exist several established medication- and psychotherapy-based treatments for anxiety \[[@pone.0199041.ref006]\], many patients still experience a poor treatment response \[[@pone.0199041.ref007], [@pone.0199041.ref008]\]. The widespread and debilitating nature of anxiety, in tandem with the frequent inadequacy of existing treatments, points to the desirability of exploring and developing novel approaches to treatment.

One particularly promising area of investigation involves manipulation of the intestinal microbiota, the diverse collection of symbiotic microorganisms residing within the human gut \[[@pone.0199041.ref009]\]. The microbiota communicates with the central nervous system via a collection of bidirectional neural, metabolic, and immune pathways known as the microbiota-gut-brain axis \[[@pone.0199041.ref010]\]. Microbiota dysfunction---most commonly, the relative loss of beneficial gut microbes---is associated with numerous types of physical and mental illness, ranging from irritable bowel syndrome to Alzheimer's disease to depression \[[@pone.0199041.ref011]\]. The experience of anxiety is closely interrelated with disordered gut function, to such an extent that commonly reported symptoms of anxiety often involve intestinal distress (e.g. upset stomach or nausea), and the severity and duration of abdominal pain are associated with elevated anxiety \[[@pone.0199041.ref012]\]. Moreover, anxiety frequently co-occurs with gastrointestinal disorders, such as irritable bowel syndrome, Crohn's disease, and ulcerative colitis \[[@pone.0199041.ref013], [@pone.0199041.ref014]\]---all of which are also linked with microbiota dysfunction \[[@pone.0199041.ref011]\]. Antibiotic use, which can profoundly reduce the gut's bacterial diversity \[[@pone.0199041.ref015]\], has also been found to increase the risk of developing an anxiety disorder later in life \[[@pone.0199041.ref016]\]. Finally, gastrointestinal disturbance caused by pathogens can elicit anxiety. Intestinal infections in humans are associated with increased risk of developing an anxiety disorder over the next two years \[[@pone.0199041.ref017]\], and healthy mice infected with a foodborne pathogen have been shown to rapidly display increased anxiety-like behavior \[[@pone.0199041.ref018]\], even in the absence of a detectable immune response \[[@pone.0199041.ref019]\], suggesting that such microorganisms can directly interact with neural pathways.

The most common way of addressing microbiota dysfunction and associated illness is through the supplemental administration of *probiotics* (beneficial microorganisms). Recent meta-analyses have found that probiotic intervention successfully reduces symptoms of both irritable bowel syndrome \[[@pone.0199041.ref020]\] and ulcerative colitis \[[@pone.0199041.ref021]\]. Probiotics are even emerging as a recommended treatment for antibiotic-associated adverse events in children \[[@pone.0199041.ref022]\]. Additionally, there is early evidence that probiotics may have psychotropic effects. Tillisch et al. \[[@pone.0199041.ref023]\], for example, demonstrated that the consumption of probiotics altered emotional processing in the brains of healthy women. Probiotics have also been shown to improve self-reported mood in otherwise healthy adults experiencing negative affect \[[@pone.0199041.ref024]\]. And animal studies have found that pretreatment with probiotics can protect against the neurological damage induced by both acute and chronic stress \[[@pone.0199041.ref025], [@pone.0199041.ref026]\]. Given that these findings came from healthy humans (and animals), they suggest that probiotics may have beneficial effects even in the absence of clinical disease. This leaves open the possibility that probiotics may be useful for both disease prevention and treatment via different underlying mechanisms.

Several recent reviews have summarized the extant literature regarding probiotics and anxiety \[[@pone.0199041.ref027]--[@pone.0199041.ref029]\]. Probiotics appear to be capable of reducing anxiety-like behavior in animals \[[@pone.0199041.ref029]\], although the impact of probiotics on anxiety in humans is less certain, with recent narrative reviews arriving at differing conclusions \[[@pone.0199041.ref027]--[@pone.0199041.ref029]\]. Notably, the overall effect of probiotics on anxiety has yet to be *quantified* for either preclinical or clinical research. Accordingly, the goal of this study was to comprehensively summarize and quantify the existing evidence on the relationship between probiotics and anxiety. To do so, systematic reviews and meta-analyses were performed on both preclinical and clinical studies, respectively.

Methods {#sec006}
=======

The preclinical and clinical reviews followed CAMARADES and PRISMA guidelines for conducting systematic reviews and meta-analyses, respectively \[[@pone.0199041.ref030], [@pone.0199041.ref031]\]. The study was not preregistered, and the protocol can be viewed at <https://dx.doi.org/10.17504/protocols.io.nsadeae>. Inclusion and exclusion criteria were selected to maximize the acquisition of all possible studies that examined the effects of probiotic administration on anxiety-like behavior in rodents or symptoms of anxiety in humans. Conference abstracts were omitted due to a lack of necessary information.

Preclinical criteria {#sec007}
--------------------

Preclinical studies were deemed eligible if they met the following inclusion criteria: 1) subjects were either rats or mice; 2) a probiotic was experimentally administered; 3) anxiety-like behavior was measured.

Studies that met one or more of the following criteria were excluded: 1) there was no matched control group; 2) the probiotic was not living at time of administration (e.g. heat-killed); 3) the probiotic was not administered directly to the tested subject (e.g. administered to the mother of infant rodent); 4) means, standard deviations, and sample sizes were not available for the measured anxiety-like behavior; 5) the full text of the study was not available in English.

Clinical criteria {#sec008}
-----------------

Clinical studies were deemed eligible if they met the following inclusion criteria: 1) the study described a randomized controlled trial; 2) at least one interventional arm administered a probiotic; 3) an anxiety scale was used as a primary or secondary measure; 4) human participants were included.

Studies that met one or more of the following criteria were excluded: 1) there was no matched control group; 2) the probiotic was not living at time of administration (e.g. heat-killed); 3) means, standard deviations, and sample sizes were not available for the anxiety measurements; 4) the full text of the study was not available in English.

Search strategy {#sec009}
---------------

The systematic literature reviews were carried out using PubMed, PsycINFO, and Web of Science databases, from the earliest record of the databases to November 2017. Search terms included Bifidobacterium OR lactobacillus OR probiotic AND anxiety (see [S1 Appendix](#pone.0199041.s001){ref-type="supplementary-material"} for the exemplar PubMed preclinical and clinical search strategies). Relevant references from the identified publications were also included. The title and abstract for each search result were then evaluated to identify potential studies, and, finally, full-texts were evaluated to determine study inclusion. Screening and evaluation were performed in a standardized manner by two independent reviewers (DR and SP). Disagreements during this process were resolved according to the following process: 1) both reviewers independently reapplied the inclusion/exclusion criteria to the study in question; 2) the two reviewers discussed the criteria until a consensus was reached; 3) in cases for which a consensus could not be reached, it was planned for the final decision to be made by an independent party (SI), although this was not necessary. The flow charts of study selection can be viewed in Figs [1](#pone.0199041.g001){ref-type="fig"} and [2](#pone.0199041.g002){ref-type="fig"}.

![Flow and selection of preclinical studies.](pone.0199041.g001){#pone.0199041.g001}

![Flow and selection of clinical studies.](pone.0199041.g002){#pone.0199041.g002}

Data collection {#sec010}
---------------

Preclinical and clinical data was extracted from selected studies using custom forms and included the following information based on CAMARADES and PRISMA guidelines \[[@pone.0199041.ref030], [@pone.0199041.ref031]\]: 1) study design characteristics, such as subject information (e.g. age, sex, health status, rodent species) and type of intervention (e.g. probiotic composition, dosage, and duration); and 2) outcome data (e.g. outcome measure, group sample sizes, mean value of effect, and group variance). Outcome data was included if it was derived from a measure of anxiety-like behavior or anxiety symptoms---equivalency across measures was assumed for each meta-analysis. Data for the final measurement of the interventional period was selected if the outcome was measured at multiple time periods. Potential study bias was evaluated using SYRCLE's risk of bias tool \[[@pone.0199041.ref032]\] for preclinical studies and the Cochrane Collaboration's risk of bias tool \[[@pone.0199041.ref033]\] for clinical studies. One reviewer (DR) extracted all included data, which was checked and confirmed by a second reviewer (SP). Disagreements between reviewers during data extraction were resolved by discussion.

One clinical study \[[@pone.0199041.ref034]\] reported only median values and interquartile range. In order to calculate an SMD, the median value of the reported data was assumed to represent the mean and the standard deviation was calculated by dividing the interquartile range by 1.35 \[[@pone.0199041.ref035]\].

When results were available only in graphical format, data was extracted using WebPlotDigitizer graph digitization software \[[@pone.0199041.ref036]\]; graph digitization has been previously shown to be a valid method for extracting study data \[[@pone.0199041.ref037]\], and WebPlotDigitizer has been recommend for use in systematic reviews \[[@pone.0199041.ref038]\].

Finally, nine preclinical and 14 clinical authors were contacted and asked to provide further information. Four preclinical and two clinical authors responded and provided additional study data, which were included in the final study selection. Extracted data can be viewed in Tables [1](#pone.0199041.t001){ref-type="table"} and [2](#pone.0199041.t002){ref-type="table"}.

10.1371/journal.pone.0199041.t001

###### Preclinical study characteristics.

![](pone.0199041.t001){#pone.0199041.t001g}

  Author, year                 Subjects                                                                              No. of subjects   Days of intervention                      Bacterial species and dosage (CFU)                                                                                                                                                                                                                                                                               Anxiety measure
  ---------------------------- ------------------------------------------------------------------------------------- ----------------- ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  Agusti A, 2017 Group 1       Male C57BL-6 mice                                                                     20                98                                        *B*. *pseudocatenulatum* CECT 7765 (1 x 10^9^)                                                                                                                                                                                                                                                                   Open field test: ↔ time in center; Light-dark test: ↔ latency
  Agusti A, 2017 Group 2       Male C57BL-6 mice fed a high-fat diet                                                 20                98                                        *B*. *pseudocatenulatum* CECT 7765 (1 x 10^9^)                                                                                                                                                                                                                                                                   Open field test: ↔ time in center; Light-dark test: ↔ latency
  Barrera-Bugueno C, 2017      Male Sprague-Dawley rats                                                              18                14                                        *L*. *casei* 54-2-33 (1 x 10^4^ CFU/mL of drinking water)                                                                                                                                                                                                                                                        Open field test: ↑ time in center, ↑ entries into center; Elevated plus maze: ↔ time in open arms, ↔ entries into open arms
  Beilharz J, 2017 Group 1     Male Sprague-Dawley rats                                                              30                36                                        *B*. *longum* DSM 24736, *B*. *infantis* DSM 24737, *B*. *breve* DSM 24732, *L*. *acidophilus* DSM 24735, *L*. *paracasei* DSM 24733, *L*. *bulgaricus* DSM 24734, *L*. *plantarum* DSM 24730, *Streptococcus thermophilus subsp*. *thermophilus* DSM 24731 (Low dose-- 2.5 x 10^9^; High dose-- 2.5 x 10^10^)   Elevated plus maze: ↔ time in open arms
  Beilharz J, 2017 Group 2     Male Sprague-Dawley rats fed a cafeteria diet                                         29                36                                        *B*. *longum* DSM 24736, *B*. *infantis* DSM 24737, *B*. *breve* DSM 24732, *L*. *acidophilus* DSM 24735, *L*. *paracasei* DSM 24733, *L*. *bulgaricus* DSM 24734, *L*. *plantarum* DSM 24730, *Streptococcus thermophilus subsp*. *thermophilus* DSM 24731 (Low dose-- 2.5 x 10^9^; High dose-- 2.5 x 10^10^)   Elevated plus maze: ↔ time in open arms
  Bercik P, 2010               Male AKR mice infected with *Trichuris muris*                                         42                30                                        *L*. *rhamnosus* NCC4007 *and B*. *longum* NCC300*1* (1 x 10^10^)                                                                                                                                                                                                                                                Light-dark box test: ↓ time in light box, ↔ latency to re-enter light box; Step-down test: ↓ latency
  Bercik P, 2011 Group 1       Male AKR mice exposed to dextran sodium sulfate                                       23                14                                        *B*. *longum* (1 x 10^10^)                                                                                                                                                                                                                                                                                       Step-down test: ↓ latency
  Bercik P, 2011 Group 2       Vagotomized male AKR mice exposed to dextran sodium sulfate                           30                14                                        *B*. *longum* (1 x 10^10^)                                                                                                                                                                                                                                                                                       Step-down test: ↔ latency
  Bharwani A, 2017 Group 1     Male C57BL/6 mice                                                                     30                28                                        *L*. *rhamnosus* JB-1 (1.67 x 10^9^)                                                                                                                                                                                                                                                                             Light-dark box test: ↔ entries into light zone
  Bharwani A, 2017 Group 2     Male C57BL/6 mice exposed to social defeat                                            31                28                                        *L*. *rhamnosus* JB-1 (1.67 x 10^9^)                                                                                                                                                                                                                                                                             Light-dark box test: ↓ entries into light zone
  Bravo J, 2011                Male BALB/c mice                                                                      36                28                                        *L*. *rhamnosus* JB-1 (1 x 10^9^)                                                                                                                                                                                                                                                                                Elevated plus maze: ↓ open arm entries, ↔ time in open arms
  Cowan C, 2016                Female Sprague-Dawley rats                                                            16                13                                        *L*. *rhamnosus* R0011 and *L*. *helveticus* R0052 (1 x 10^9^ CFU/mL of drinking water)                                                                                                                                                                                                                          Elevated plus maze: ↔ open arm entries, ↔ time in open arms, ↔ latency
  Divyashri G, 2015            Male CFT-Swiss mice                                                                   24                28                                        *Enterococcus faecium* CFR 3003 (Low dose-- 1 x 10^4^; High dose-- 1 x 10^8^) or *L*. *rhamnosus* GG MTCC 1408 (1 x 10^8^)                                                                                                                                                                                       Elevated plus maze: ↓ open arm entries, ↓ time in open arms; Open field test: ↔ entries into center, ↔ time in center
  Emge J, 2016 Group 1         Male and female C57BL/6 mice                                                          10                15                                        *L*. *rhamnosus* R0011 and *L*. *helveticus* R0052 (2 x 10^9^)                                                                                                                                                                                                                                                   Light-dark box test: ↔ time in light box
  Emge J, 2016 Group 2         Male and female C57BL/6 mice exposed to dextran sodium sulfate                        20                15                                        *L*. *rhamnosus* R0011 and *L*. *helveticus* R0052 (2 x 10^9^)                                                                                                                                                                                                                                                   Light-dark box test: ↓ time in light box
  Jang H, 2017                 Male ICR mice exposed to immobilization stress                                        24                3                                         *B*. *adolescentis* IM38 (Low dose-- 2 x 10^8^; Medium dose-- 1 x 10^9^; High dose-- 5 x 10^9^ CFU)                                                                                                                                                                                                              Elevated plus maze: ↓ open arm entries, ↓ time in open arms
  Liang S, 2015                Male specific-pathogen-free Sprague-Dawley rats exposed to chronic restraint stress   16                22                                        *L*. *helveticus* NS8 (1 x 10^9^ CFU/mL of drinking water)                                                                                                                                                                                                                                                       Elevated plus maze: ↔ open arm entries, ↓ time in open arms; Open field test: ↔ time in center
  Liu W, 2016 Group 1          Male GF C57BL/BJNarl mice                                                             20                16                                        *L*. *plantarum* PS128 (1 x 10^9^)                                                                                                                                                                                                                                                                               Elevated plus maze: ↓ time in open arms / time in closed arms ratio; Open field test: ↔ time in center
  Liu W, 2016 Group 2          Male C57BL/6J mice                                                                    12                16                                        *L*. *plantarum* PS128 (1 x 10^9^)                                                                                                                                                                                                                                                                               Elevated plus maze: ↓ time in open arms; Open field test: ↓ time in center
  Liu Y, 2016 Group 1          Male C57BL/6J mice exposed to early-life stress                                       20                28                                        *L*. *plantarum* PS128 (1 x 10^9^)                                                                                                                                                                                                                                                                               Elevated plus maze: ↔ time in open arms; Open field test: ↔ time in center
  Liu Y, 2016 Group 2          Male C57BL/6J mice                                                                    18                28                                        *L*. *plantarum* PS128 (1 x 10^9^)                                                                                                                                                                                                                                                                               Elevated plus maze: ↓ time in open arms; Open field test: ↓ time in center
  Luo J, 2014                  Male specific-pathogen-free Sprague-Dawley rats with induced hyperammonemia           12                14                                        *L*. *helveticus* NS8 (1 x 10^9^)                                                                                                                                                                                                                                                                                Elevated plus maze: ↓ open arm entries, ↔ time in open arms
  Mackos A, 2013 Group 1       Male outbred CD-1 mice                                                                36                12                                        *L*. *reuteri* 23272 (1.5 x 10^8^)                                                                                                                                                                                                                                                                               Open field test: ↔ time spent in center
  Mackos A, 2013 Group 2       Male outbred CD-1 mice exposed to prolonged-restraint                                 18                12                                        *L*. *reuteri* 23272 (1.5 x 10^8^)                                                                                                                                                                                                                                                                               Open field test: ↔ time spent in center
  Matthews D, 2013             Male specific-pathogen-free BALB/c mice                                               18                Administered several times over 7 weeks   *Mycobacterium vaccae* 15,483 (4.5 x 10^5^)                                                                                                                                                                                                                                                                      Anxiety-like behaviors during maze task: ↔ immobilization, ↔ grooming, ↔ latency to start
  McKernan D, 2010 Group 1     Male Sprague-Dawley rats                                                              40                14                                        *L*. *salivarius* UCC118 (1 x 10^9^); or *B*. *infantis* 35624 (1 x 10^9^); or *B*. *breve* UCC2003 (1 x 10^9^)                                                                                                                                                                                                  Open field test: ↔ time in center
  McKernan D, 2010 Group 2     Male Wistar-Kyoto rats                                                                40                14                                        *L*. *salivarius* UCC118 (1 x 10^9^); or *B*. *infantis* 35624 (1 x 10^9^); or *B*. *breve* UCC2003 (1 x 10^9^)                                                                                                                                                                                                  Open field test: ↔ time in center
  Moya-Perez A, 2017 Group 1   Male C57Bl/6J mice                                                                    18                20                                        *B*. *pseudocatenulatum* CECT 7765 (1 x 10^8^ CFU)                                                                                                                                                                                                                                                               Elevated plus maze: ↔ time in open arms
  Moya-Perez A, 2017 Group 2   Male C57Bl/6J mice exposed to early-life stress                                       18                20                                        *B*. *pseudocatenulatum* CECT 7765 (1 x 10^8^ CFU)                                                                                                                                                                                                                                                               Elevated plus maze: ↓ time in open arms; Open field test: ↔ entries into center
  Smith C, 2014 Group 1        Male and female wild-type *Rag1*^*-/-*^ mice                                          12                28                                        *L*. *rhamnosus* R0011 and *L*. *helveticus* R0052 (6 x 10^9^)                                                                                                                                                                                                                                                   Light-dark box test: ↓ time in light box
  Smith C, 2014 Group 2        Male and female wild-type *Rag1*^*-/-*^ mice exposed to water avoidance stress        10                28                                        *L*. *rhamnosus* R0011 and *L*. *helveticus* R0052 (6 x 10^9^)                                                                                                                                                                                                                                                   Light-dark box test: ↓ time in light box
  Vanhaecke T, 2017            Sprague-Dawley rats                                                                   12                15                                        *L*. *fermentum* CECT 5716 (1 x 10^9^ CFU/100g body weight)                                                                                                                                                                                                                                                      Elevated plus maze: ↔ open arm entries
  Wang T, 2015                 Male Sprague-Dawley rats exposed to an antibiotic                                     20                30                                        *L*. *fermentum* NS9 (1 x 10^9^ CFU/mL of drinking water)                                                                                                                                                                                                                                                        Elevated plus maze: ↓ open arm entries

↓ and ↑ represent a statistically significant decrease or increase (respectively) in anxiety-like behavior in at least one probiotic treatment group, while ↔ represents a nonsignificant or unclear change.

10.1371/journal.pone.0199041.t002

###### Clinical study characteristics.
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  Author, year             Subjects (age)                                                        No. of subjects         Intervention (days)        Bacterial species and dosage (CFU)                                                                                                                                        Anxiety scale
  ------------------------ --------------------------------------------------------------------- ----------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------
  Kato-Kataoka A, 2016     Healthy 4^th^-grade medical students (average age \~23)               47                      Milk (56)                  *L*. *casei Shirota* YIT 9029 (1 x 10^11^)                                                                                                                                ↔ STAI-state
  Kelly J, 2017            Healthy adults (average age 24.6, 20--33 range)                       29 (crossover design)   Capsule (28)               *L*. *rhamnosus* JB-1 (1 x 10^9^)                                                                                                                                         ↔ STAI-state, ↔ STAI-trait, and ↔ BAI
  Lorenzo-Zuniga V, 2014   Adults with IBS with diarrhea (20--70 range)                          71                      Capsule (42)               *L*. *plantarum* CECT 7484, *L*. *plantarum* CECT 7485, and *Pediococcus acidilactici* CECT 7483 (Low dose-- 3--6 x 10^9^; High dose-- 1--3 x 10^10^)                     ↓ Visceral Sensitivity Index
  Lyra A, 2016             Adults with IBS (18--65 range)                                        332                     Capsule (84)               *L*. *acidophilus* NCFM (Low dose-- 1 x 10^9^; High dose-- 1 x 10^10^)                                                                                                    ↔ HADS-anxiety subscale
  Marcos A, 2004           Healthy students (18--23 range)                                       136                     Milk (42)                  *L*. *delbrueckii* subsp. *bulgaricus* (2 x 10^9^), *Streptococcus salivarius* subsp. *thermophilus* (2 x 10^10^), *L*. *casei* DN114001 (2 x 10^10^)                     ↔ STAI-state and ↔ STAI-trait
  Messaoudi M, 2011        Healthy adults (average age \~43)                                     55                      Powder (30)                *L*. *helveticus* R0052 *and B*. *longum* R0175 (3 x 10^9^)                                                                                                               ↔ HADS-anxiety and ↔ HSCL-90 anxiety
  Pinto-Sanchez M, 2017    Adults with IBS (median age \~43)                                     38                      Powder (42)                *B*. *longum* NCC3001 (1 x 10^10^)                                                                                                                                        ↔ HADS-anxiety, ↔ STAI-state, and ↔ STAI-trait
  Romijn A, 2017           Adults (age 16+) with at least moderate low mood (average age \~35)   79                      Powder (56)                *L*. *helveticus* R0052 *and B*. *longum* R0175 (2 x 10^10^)                                                                                                              ↔ DASS-42 anxiety subscale
  Simren M, 2010           Adults with IBS (average age \~43)                                    67                      Yogurt (56)                *L*. *paracasei* subsp. *paracasei* F19, *L*. *acidophilus* La5, and *B*. *lactis* Bb12 (2 x 10^10^)                                                                      ↔ HADS-anxiety subscale
  Slykerman R, 2017        Pregnant women (average age \~34)                                     379                     Capsule (Up to \~1 year)   *L*. *rhamnosus* HN001 (6 x 10^9^)                                                                                                                                        ↓ STAI-6 item version
  Steenbergen L, 2015      Healthy adults (average age \~20)                                     40                      Powder (28)                *B*. *bifidum* W23, *B*. *lactis* W52, *L*. *acidophilus* W37, *L*. *brevis* W63, *L*. *casei* W56, *L*. *salivarius* W24, *Lactococcus lactis* W19 and W58 (5 x 10^9^)   ↔ BAI
  Takada M, 2016           Healthy 4^th^-grade medical students (average age \~23)               140                     Milk (56)                  *L*. *casei Shirota* YIT 9029 (1 x 10^11^)                                                                                                                                ↔ STAI-state
  Takada M, 2017           Healthy 4^th^-grade medical students (average age \~23)               94                      Milk (77)                  *L*. *casei Shirota* YIT 9029 (1 x 10^11^)                                                                                                                                ↔ STAI-state
  Yang H, 2016             Patients with cancer (average age \~58)                               20                      Capsule (14)               *Clostridium butyricum* (CFU not reported-- 420 mg per capsule)                                                                                                           ↓ HAMA

STAI = State-Trait Anxiety Inventory; BAI = Beck Anxiety Inventory; HADS = Hospital Anxiety and Depression Scale; HSCL-90 = Hopkins Symptom Checklist-90; DASS = Depression Anxiety Stress Scales; HAMA = Hamilton Anxiety Rating Scale.

↓ and ↑ represent a statistically significant decrease or increase (respectively) in anxiety-like behavior in at least one probiotic treatment group, while ↔ represents a nonsignificant or unclear change.

Statistical analyses {#sec011}
--------------------

The preclinical and clinical meta-analyses were performed with R 3.2.5 software \[[@pone.0199041.ref039]\]. All analyses were pre-specified unless otherwise stated. For each included study, the standardized mean difference (SMD; also known as Hedges' g) between the probiotic and matched control groups was calculated for all continuous measures of anxiety-like behavior or anxiety symptoms. Confidence intervals were calculated for each SMD using a standard normal distribution. For both preclinical and clinical studies, sample size, probiotic duration, and probiotic dose were assessed as moderating variables in individual meta-regressions. Separate subgroup analyses were conducted on diseased (receiving experimental manipulations in addition to probiotic or vehicle intervention) and naïve animals (receiving only probiotic or vehicle intervention), as well as mouse and rat samples. Exploratory subgroup analyses were also performed on studies that used matching individual or combined probiotic species, provided that the probiotic was tested in at least three experimental groups. In humans, subgroup analyses were conducted on clinical (individuals with a medical or psychological illness) and healthy samples. Multiple subgroups within a single study (e.g. different rodent strains or experimental conditions) were included as independent SMDs, provided that each treatment group had a separate, matched control group. When multiple probiotic treatment groups were compared against the same control group, the results from the different probiotic groups were combined, and the SMD was calculated from the combined results \[[@pone.0199041.ref035]\].

If multiple measures of anxiety-like behavior or anxiety symptoms were reported in a single study, a separate SMD was calculated for each outcome. To account for the dependency between SMDs measured in the same sample, robust variance estimation (RVE) meta-analyses were used to estimate preclinical and clinical summary SMDs. RVE meta-analysis is a form of random-effects meta-analysis that has been shown to address SMD dependency when the covariances between outcomes measured in the same study are unknown \[[@pone.0199041.ref040]\]. In other words, RVE allows for multiple outcomes from a single study to be included in a meta-analysis as separate SMDs; the weights are adjusted accordingly (i.e. the SMDs share a single study weight). Precision (i.e. inverse variance) was used to weight SMDs.

One clinical study included in the final analysis \[[@pone.0199041.ref041]\] utilized a cross-over experimental design, but did not report the correlation between the interventional periods. A correlation of 0.5 was imputed to calculate the standard error of the SMD for the study. A sensitivity analysis, using alternative correlational values to calculate the standard error, revealed that the choice of correlational value did not impact the overall results of the clinical meta-analysis.

I^2^ was used to evaluate between-study heterogeneity. Values of I^2^ more than 25%, 50%, and 75% were selected to reflect low, moderate, and high heterogeneity, respectively, in accordance with guidelines described by Higgins et al. \[[@pone.0199041.ref042]\]. Potential publication bias was assessed via funnel plot and Egger test \[[@pone.0199041.ref043]\].

Results {#sec012}
=======

Preclinical meta-analysis {#sec013}
-------------------------

### Study selection and characteristics {#sec014}

Twenty-two studies \[[@pone.0199041.ref044]--[@pone.0199041.ref065]\] with 33 independent experimental groups and 743 rodent subjects were included in the preclinical meta-analysis ([Fig 1](#pone.0199041.g001){ref-type="fig"} and [Table 1](#pone.0199041.t001){ref-type="table"}). Eight studies used rats as experimental subjects, while the other 14 used mice. All but four studies \[[@pone.0199041.ref051], [@pone.0199041.ref053], [@pone.0199041.ref063], [@pone.0199041.ref064]\] reported using only male rodents. Fifteen of the 33 experimental groups modeled a form of disease and were exposed to additional manipulation, such as social defeat \[[@pone.0199041.ref049]\], early-life stress \[[@pone.0199041.ref057]\], or induced chronic colitis \[[@pone.0199041.ref047]\]. Thirteen studies assessed anxiety-like behavior using an elevated plus maze, five studies used a light-dark box test, two studies used a step-down test, nine studies used an open field test, and one study observed behaviors related to anxiety during a maze task (eight studies employed multiple paradigms). Species from the *Lactobacillus*, *Bifidobacterium*, *Mycobacterium*, and *Streptococcus* genera were used as probiotics.

### Bias assessment {#sec015}

[Table 3](#pone.0199041.t003){ref-type="table"} shows the assessment of the risk of bias for the included studies. No study provided sufficient detail regarding performance bias or detection bias, and only one study provided detail regarding selection bias. This lack of reporting makes it difficult, if not impossible, to accurately determine risk of bias. More detail was provided regarding the risk of attrition bias, reporting bias, and other bias. Four studies had a high risk of reporting bias \[[@pone.0199041.ref049], [@pone.0199041.ref057], [@pone.0199041.ref060], [@pone.0199041.ref062]\], and three studies had a high risk of other bias \[[@pone.0199041.ref045], [@pone.0199041.ref053], [@pone.0199041.ref059]\]. A separate sensitivity analysis revealed that removal of these studies did not substantively impact the results. Overall, the risk of bias for each included study is unclear.

10.1371/journal.pone.0199041.t003

###### Preclinical risk of bias assessment.
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  Study                         Baseline characteristics   Incomplete outcome data   Selective reporting   Other bias
  ----------------------------- -------------------------- ------------------------- --------------------- ------------
  Agusti et al. 2017            Unclear                    Low                       Low                   Low
  Barrera-Bugueno et al. 2017   Unclear                    Low                       Low                   High
  Beilharz et al. 2017          Unclear                    Low                       Low                   Low
  Bercik et al. 2010            Unclear                    Low                       Low                   Unclear
  Bercik et al. 2011            Unclear                    Unclear                   Low                   Unclear
  Bharwani et al. 2017          Unclear                    Unclear                   High                  Unclear
  Bravo et al. 2011             Unclear                    Unclear                   Low                   Low
  Cowan et al. 2016             Low                        Unclear                   Low                   Low
  Divyashri et al. 2015         Unclear                    Unclear                   Low                   Unclear
  Emge et al. 2016              Unclear                    Unclear                   Low                   High
  Jang et al. 2017              Unclear                    Low                       Low                   Low
  Liang et al. 2015             Unclear                    Low                       Low                   Low
  Liu, W et al. 2016            Unclear                    Low                       Low                   Low
  Liu, Y et al. 2016            Unclear                    Unclear                   High                  Low
  Luo et al. 2014               Unclear                    Low                       Low                   Low
  Mackos et al. 2013            Unclear                    Low                       Low                   High
  Matthews et al. 2013          Unclear                    Low                       High                  Low
  McKernan et al. 2010          Unclear                    Low                       Low                   Unclear
  Moya-Perez et al. 2017        Unclear                    Low                       High                  Low
  Smith et al. 2014             Unclear                    Unclear                   Low                   Unclear
  Vanhaecke et al. 2017         Unclear                    Unclear                   Low                   Unclear
  Wang et al. 2015              Unclear                    Low                       Low                   Unclear

Risk of bias relating to Sequence generation, Allocation concealment, Random housing, Blinding (intervention), Random outcome assessment, and Blinding (assessment) was Unclear for all included studies, and as such these domains have been omitted from the table

### Probiotic efficacy {#sec016}

Combining standardized mean differences (SMDs) for the 33 included experimental groups revealed a pooled SMD of -0.47 (95% CI -0.77 ---0.16, *p* = 0.004; [Fig 3](#pone.0199041.g003){ref-type="fig"}). Probiotic administration, compared to placebo, was shown to significantly reduce anxiety-like behavior in rodents. Neither sample size (β = 0.01, 95% CI: -0.02--0.04, *p* = 0.432), probiotic duration (β = 0.01, 95% CI: -0.02--0.04, *p* = 0.372), nor probiotic dose (β = -0.006, 95% CI: -0.12--0.11, *p* = 0.906) provided a significant moderating influence.

![Forest plot of preclinical studies investigating the effect of probiotics on anxiety-like behavior.\
SMD = Standardized mean difference; CI = Confidence interval. An aggregate SMD is displayed for each experimental group. Measure-specific SMDs can be viewed in [S1 Fig](#pone.0199041.s003){ref-type="supplementary-material"}.](pone.0199041.g003){#pone.0199041.g003}

Subgroup analyses revealed that probiotic administration significantly reduced anxiety-like behavior in diseased (SMD = -0.81, 95% CI: -1.27 - -0.35, p = 0.002), but not in naïve animals (SMD = -0.16, 95% CI: -0.58--0.26, *p* = 0.433). Furthermore, probiotics significantly reduced anxiety-like behavior in mice (SMD = -0.58, 95% CI: -0.90 ---0.26, *p* = 0.001), but not rats (SMD = -0.17, 95% CI: -1.07--0.73, *p* = 0.678).

Four probiotics were selected for additional subgroup analyses based on their utilization in multiple trials: *Lactobacillus* (*L*.) *rhamnosus*, *Bifidobacterium* (*B*.) *pseudocatenulatum*, *L*. *plantarum* (four experimental groups each), and combined *L*. *rhamnosus* and *L*. *helveticus* (five experimental groups). Only *L*. *rhamnosus* was shown to significantly reduce anxiety-like behavior (SMD = -0.77, 95% CI: -1.40 ---0.13, *p* = 0.018). Anxiety-like behavior was not affected by *B*. *pseudocatenulatum* (SMD = -0.24, 95% CI: -0.76--0.28, *p* = 0.368), *L*. *plantarum* (SMD = -0.50, 95% CI: -1.37--0.38, *p* = 0.264), or combined *L*. *rhamnosus* and *L*. *helveticus* (SMD = -0.61, 95% CI: -1.54--0.32, *p* = 0.201).

### Publication bias and heterogeneity {#sec017}

Visual inspection of a funnel plot ([Fig 4](#pone.0199041.g004){ref-type="fig"}) and the use of an Egger test (*t* = -0.15, *df* = 55, *p* = 0.880) did not suggest the presence of publication bias, although several SMDs fell outside of the expected area of the funnel plot. Factors other than publication bias can contribute to funnel plot asymmetry, including heterogeneity and other forms of bias \[[@pone.0199041.ref066]\]. There was moderate heterogeneity across the 33 experimental groups (I^2^ = 70.5%), indicating that 70.5% of the variation between study outcomes is attributable to inconsistency between the studies. Funnel plot asymmetry and heterogeneity are well-documented problems present in meta-analyses of animal research \[[@pone.0199041.ref067]\]. Factors such as subject species/strain, sample size, and additional experimental conditions can contribute to these issues, although inclusion of study characteristics as moderating variables and subgroup analyses did not reduce heterogeneity in the present analysis.

![Funnel plot of preclinical standardized mean differences.](pone.0199041.g004){#pone.0199041.g004}

Clinical meta-analysis {#sec018}
----------------------

### Study selection and characteristics {#sec019}

Fourteen studies \[[@pone.0199041.ref034], [@pone.0199041.ref041], [@pone.0199041.ref068]--[@pone.0199041.ref079]\], consisting of 1527 individuals, were included in the clinical meta-analysis ([Fig 2](#pone.0199041.g002){ref-type="fig"} and [Table 2](#pone.0199041.t002){ref-type="table"}). Eight studies assessed the effect of probiotic administration on healthy samples, while six studies did so with clinical samples. Of the six studies that used clinical participants, four studies investigated participants with irritable bowel syndrome \[[@pone.0199041.ref069], [@pone.0199041.ref070], [@pone.0199041.ref072], [@pone.0199041.ref074]\], one study investigated participants with at least moderate mood disturbance \[[@pone.0199041.ref073]\], and one study investigated participants with cancer \[[@pone.0199041.ref079]\]. Two studies divided their participants receiving probiotic into low and high dose groups \[[@pone.0199041.ref069], [@pone.0199041.ref070]\]. One study used a crossover randomized controlled trial design \[[@pone.0199041.ref041]\], while the other 13 studies used a parallel design. Species from the *Lactobacillus*, *Bifidobacterium*, *Pediococcus*, *Streptococcus*, and *Clostridium* genera were used as probiotics.

### Bias assessment {#sec020}

The assessment for the included studies' risk of bias can be viewed in [Table 4](#pone.0199041.t004){ref-type="table"}. All 14 studies had a low risk of attrition bias, and most studies had a low risk of both reporting and other bias. Less than half of the studies included details regarding allocation concealment. Overall, the risk of bias for each included study ranged from low to unclear.

10.1371/journal.pone.0199041.t004

###### Clinical risk of bias assessment.

![](pone.0199041.t004){#pone.0199041.t004g}

  Study                        Random sequence generation   Allocation concealment   Blinding of participants   Blinding of assessor   Incomplete outcome data   Selective reporting   Other bias
  ---------------------------- ---------------------------- ------------------------ -------------------------- ---------------------- ------------------------- --------------------- ------------
  Kato-Kataoka et al. 2016     Unclear                      Unclear                  Unclear                    Unclear                Low                       Low                   Low
  Kelly et al. 2017            Unclear                      Unclear                  Unclear                    Unclear                Low                       Unclear               Unclear
  Lorenzo-Zuniga et al. 2014   Low                          Unclear                  Low                        Low                    Low                       Low                   Low
  Lyra et al. 2016             Low                          Unclear                  Low                        Low                    Low                       Low                   Low
  Marcos et al. 2004           Unclear                      Unclear                  Unclear                    Unclear                Low                       Low                   Unclear
  Messaoudi et al. 2011        Low                          Low                      Low                        Low                    Low                       Unclear               Low
  Pinto-Sanchez et al.         Low                          Low                      Low                        Low                    Low                       Low                   Low
  Romijn et al. 2017           Low                          Low                      Low                        Low                    Low                       Low                   Low
  Simren et al. 2010           Unclear                      Low                      Low                        Low                    Low                       Low                   Low
  Slykerman et al. 2015        Unclear                      Unclear                  Low                        Low                    Low                       Low                   Low
  Steenbergen et al. 2015      Unclear                      Unclear                  Low                        Low                    Low                       Low                   Low
  Takada et al. 2016           Low                          Unclear                  Unclear                    Unclear                Low                       Low                   Low
  Takada et al. 2017           Low                          Low                      Unclear                    Unclear                Low                       Low                   Low
  Yang et al. 2016             Unclear                      Unclear                  Unclear                    Unclear                Low                       Low                   Unclear

### Probiotic efficacy {#sec021}

Combining standardized mean differences (SMDs) for the 14 included studies revealed a pooled SMD of -0.12 (95% CI: -0.29--0.05, *p* = 0.151; [Fig 5](#pone.0199041.g005){ref-type="fig"}), indicating that probiotic administration did not result in a significant reduction of anxiety. Neither sample size (β = 0.00, 95% CI: 0.00--0.00, *p* = 0.746), probiotic duration (β = 0.00, 95% CI: -0.01--0.01, *p* = 0.915), nor probiotic dose (β = 0.00, 95% CI: -0.01--0.01, *p* = 0.433) provided a moderating influence. Additionally, subgroup analyses revealed that probiotic administration did not result in a significant reduction of anxiety in healthy (SMD = -0.10, 95% CI: -0.33--0.13, *p* = 0.283) or clinical participants (SMD = -0.33, 95% CI: -1.08--0.43, *p* = 0.312).

![Forest plot of clinical studies investigating the effect of probiotics on anxiety-like behavior.\
SMD = Standardized mean difference; CI = Confidence interval; STAI = State-Trait Anxiety Inventory; BAI = Beck Anxiety Inventory; VSI = Visceral Sensitivity Index; HADS = Hospital Anxiety and Depression Scale; HSCL-90 = Hopkins Symptom Checklist-90; DASS = Depression Anxiety Stress Scales; HAM-A = Hamilton Anxiety Rating Scale.](pone.0199041.g005){#pone.0199041.g005}

### Publication bias and heterogeneity {#sec022}

Visual inspection of [Fig 6](#pone.0199041.g006){ref-type="fig"} demonstrated symmetry, apart from one study \[[@pone.0199041.ref079]\], while the use of an Egger test similarly did not suggest the presence of publication bias (*t* = 1.52, *df* = 18, *p* = 0.146). There was also moderate heterogeneity across the 14 included studies (I^2^ = 61.8%). Removal of the study by Yang et al. \[[@pone.0199041.ref079]\] resulted in low heterogeneity (I^2^ = 21.7%); however, the results of the meta-analysis remained unchanged.

![Funnel plot of clinical standardized mean differences.](pone.0199041.g006){#pone.0199041.g006}

Discussion {#sec023}
==========

The present systematic review and meta-analysis of 22 preclinical studies (743 animals) revealed a significant overall effect of probiotic administration in reducing anxiety-like behavior in rodents. The observed pooled standardized mean difference (SMD) of -0.47 reflects a medium-sized effect of probiotic interventions in comparison with non-probiotic controls. At the level of individual trials, 12 of the 22 included animal studies found that probiotics significantly reduced anxiety-like behavior on at least one outcome measure, with the remaining 10 studies finding either no effect or (in one case) *increased* anxiety-like behavior.

In contrast, only 3 of the 14 included clinical studies (encompassing 1527 individuals) found that probiotics significantly reduced symptoms of anxiety. Notably, probiotics also yielded no overall anxiolytic effects in the present meta-analysis. Subgroup analyses likewise observed no significant probiotic effects among either healthy or diseased human participants. These findings stand in stark contrast with the conclusions of two recent qualitative reviews, both of which proposed that probiotics may have anxiolytic properties \[[@pone.0199041.ref027], [@pone.0199041.ref029]\]. However, unlike such reviews, the present study utilized meta-analytic techniques to quantitatively evaluate the magnitude of probiotic effects on anxiety, as well as the degree to which the reported effects of different studies varied. This approach also enabled the inclusion of multiple measures of anxiety from relevant studies in a single summary analysis. As such, the reported results provide the only comprehensive review to date of the relevant research.

In perhaps this study's most important set of subgroup analyses, probiotics were found to successfully reduce anxiety-like behavior in diseased, but not in healthy, rodents. Although the utilized disease models varied considerably across studies---ranging from rodents with induced intestinal inflammation \[[@pone.0199041.ref047], [@pone.0199041.ref048], [@pone.0199041.ref053]\] to those exposed to stressful conditions \[[@pone.0199041.ref049], [@pone.0199041.ref054], [@pone.0199041.ref059]\] to those fed an unhealthy diet \[[@pone.0199041.ref044], [@pone.0199041.ref046]\]---they all reflected the presence of a pathological state that might be associated with elevated stress or anxious arousal. It is possible, therefore, that the anxiolytic effects of probiotics only occur above a baseline threshold level of heightened anxious arousal. If so, this phenomenon could help explain the absence of an observed therapeutic (anti-anxiety) effect of probiotic supplementation in our meta-analysis of human trials, inasmuch as none of the included studies specifically recruited participants on the basis of anxiety-related symptomatology. Indeed, the majority (8) of included studies simply assessed the effect of probiotics on self-reported anxiety levels among healthy, non-clinical participants. Another four studies recruited patients with irritable bowel syndrome (IBS) \[[@pone.0199041.ref069], [@pone.0199041.ref070], [@pone.0199041.ref072], [@pone.0199041.ref074]\], and although such patients may sometimes experience elevated anxiety \[[@pone.0199041.ref013]\], it is not a defining feature of the disorder. The remaining two clinical studies likewise selected participants based on criteria other than anxiety severity \[[@pone.0199041.ref073], [@pone.0199041.ref079]\]. Simply put: the general absence of clinically salient anxiety among human participants in the extant probiotic literature may have obscured any potential anxiolytic effects. Accordingly, it will be useful and informative for future investigations in this area to explicitly target participants characterized by clinically significant anxiety.

The discrepancy between preclinical and clinical studies may also be due to differences in the way that anxiety was evaluated across these groups. Whereas anxiety in humans was assessed entirely through self-report measures, anxiety in rodents was assessed through behavioral observations. There is evidence that, during the treatment of emotion-based disorders such as depression or anxiety, cognitive and behavioral processes improve prior to any subjective awareness of recovery, which may take weeks to be fully realized \[[@pone.0199041.ref080]\]. It is possible that self-report questionnaires of anxiety are not sensitive enough to detect probiotic-induced anxiolysis, at least under typically studied treatment durations. Only half of the included clinical studies administered probiotics for at least eight weeks, which is often used as an upper cutoff when determining response to pharmacological treatments such as antidepressants. In addition to longer treatment durations, alternative forms of assessment, such as functional imaging techniques, may be needed in clinical studies to accurately measure the anxiolytic impact of probiotics. Encouragingly, at least one study to date has demonstrated that probiotics can alter emotional processing as measured by functional imaging \[[@pone.0199041.ref023]\].

In terms of the specific probiotic supplement regimens employed, the 14 relevant human trials to date were characterized by such a high level of between-study heterogeneity that more fine-grained analyses of individual probiotic species were precluded. However, the preclinical studies were subjected to further subgroup analyses on the basis of four species of probiotic that were each utilized in several studies. Among these four candidate species, only *Lactobacillus* (*L*.) *rhamnosus* was found to significantly reduce anxiety-like behavior, with a rather large standardized mean difference (SMD) of -0.77 across the relevant trials \[[@pone.0199041.ref049], [@pone.0199041.ref050], [@pone.0199041.ref052]\]. Each of the *L*. *rhamnosus* studies used an administration duration of 28 days, with specific strains consisting of *L*. *rhamnosus* JB-1 \[[@pone.0199041.ref049], [@pone.0199041.ref050]\] and *L*. *rhamnosus* GG MTCC 1408 \[[@pone.0199041.ref052]\]. Notably, *L*. *rhamnosus* was also the probiotic species used in one of the only studies to observe a significant anxiolytic effect in humans \[[@pone.0199041.ref075]\]. This particular species has been widely investigated, and has been shown to attenuate the symptoms of various gastrointestinal and allergic diseases \[[@pone.0199041.ref081]\]. Based on our results, it appears that *L*. *rhamnosus* may also have psychotropic properties, and should be further and more extensively investigated for its anxiolytic potential.

Other probiotic species that were shown to significantly reduce anxiety-like behavior in individual rodent studies include *L*. *helveticus* \[[@pone.0199041.ref055], [@pone.0199041.ref058]\], *Bifidobacterium* (*B*.) *longum* \[[@pone.0199041.ref047]\], *B*. *adolescentis* \[[@pone.0199041.ref054]\], and combined *L*. *rhamnosus* and *B*. *longum* \[[@pone.0199041.ref048]\]. Conversely, one species of probiotic was shown to *increase* anxiety-like behavior in rodents: *L*. *casei* \[[@pone.0199041.ref045]\]. While *Lactobacillus* and *Bifidobacterium* species of bacteria are the most commonly investigated probiotics \[[@pone.0199041.ref082]\], the different species are not identical, and even strains within the same species can have unique effects on the body \[[@pone.0199041.ref083]\]. Because of this, candidate probiotics require extensive study and characterization prior to clinical application.

Notably, the dose-response curve of probiotics also remains almost completely uninvestigated when it comes to their potential psychoactive effects. In fact, the weight-adjusted probiotic dosages (colony-forming units per gram of body weight) used in the rodent trials reviewed herein were typically *hundreds of times larger* than the corresponding dosages used in the human trials. And this fact raises the possibility that the significant anxiolytic effect of supplementation in the rodent meta-analysis and the null effect in the human meta-analysis both reflect---at least in part---the much higher dosing schedule utilized with the rodents. The same consideration could also help explain the more robust anxiolytic effect observed among mice versus rats, as the mice typically received higher weight-adjusted probiotic doses by virtue of being about 10 times smaller than rats, on average. By extension, it is conceivable that future investigators could discover the most effectively anxiolytic probiotic dosages in humans to be dozens---or perhaps even hundreds---of times higher than those employed to date.

It is possible that probiotics reduce anxiety-like behavior by influencing the immune system, which is a primary component of the microbiota-gut-brain axis \[[@pone.0199041.ref010]\]. Many of the included preclinical studies found the anxiolytic effects of probiotics to be accompanied by beneficial alterations in immune functioning \[[@pone.0199041.ref049], [@pone.0199041.ref052], [@pone.0199041.ref054], [@pone.0199041.ref055], [@pone.0199041.ref057], [@pone.0199041.ref058]\]. And the microbiota continuously stimulates a complex and dynamic immune response by interacting with the intestinal barrier \[[@pone.0199041.ref084]\]. Germ-free mice without a microbiota have an impaired immune response \[[@pone.0199041.ref085]\], and induced dysbiosis has been linked with inflammatory bowel disease \[[@pone.0199041.ref086]\]. As such, probiotics may improve mental health by restoring microbiota-mediated immune activation to an adaptive level. Another possibility is that the anxiolytic effects observed herein were due to an alteration of activity in the vagus nerve, also a major connection between the microbiota and the brain \[[@pone.0199041.ref010]\]. In fact, two of the reviewed preclinical studies found that inhibition of the vagus nerve---a major pathway between the microbiota and the central nervous system \[[@pone.0199041.ref087]\]---prevented probiotic-induced reductions of anxiety-like behavior \[[@pone.0199041.ref047], [@pone.0199041.ref050]\].

It should be emphasized that none of the analyzed preclinical studies provided sufficient detail regarding risk of selection, performance, or detection biases, making it so that the overall risk of bias for each preclinical study was unclear. Most clinical studies were similarly rated as having an unclear risk of bias, especially within the domains of randomization, allocation concealment, and blinding. As such, there is some concern that bias present in the included studies may be affecting the observed results. Failure to account for potential biases has been shown to influence study outcomes and can lead to overestimation of observed effects \[[@pone.0199041.ref088], [@pone.0199041.ref089]\]. For example, animal studies that do not employ randomization procedures have been found to have significantly higher standardized mean differences than those that do \[[@pone.0199041.ref090]\]. Furthermore, an incomplete description of study methods can complicate replication efforts and evaluations of study reliability. Poor reporting of bias risk criteria is a particular issue within the broader preclinical literature, and certainly not isolated to probiotic research \[[@pone.0199041.ref091]\]. The use of appropriate randomization, allocation concealment, and blinding procedures, as well as proper reporting thereof, will greatly aid preclinical and clinical probiotic development research.

Two of the 14 included clinical studies found that probiotic administration resulted in a significant improvement of anxiety, compared to placebo, without contributing substantially to statistical heterogeneity \[[@pone.0199041.ref069], [@pone.0199041.ref075]\]. Notably, Slykerman et al. \[[@pone.0199041.ref075]\] administered probiotics to pregnant women for up to one year, the longest duration of any study included in this analysis. Because the composition of the microbiota is relatively stable and at least somewhat resistant to change induced by external disturbances, including probiotics \[[@pone.0199041.ref092]\]---and in light of evidence that probiotics may only exert transient effects on the body \[[@pone.0199041.ref093], [@pone.0199041.ref094]\]---it is possible that long-term probiotic supplementation is necessary to significantly alter the microbiota composition and induce beneficial changes in psychological functioning. It may also be that pregnancy represents a unique window for probiotic-based intervention, as there is evidence that the microbiota changes drastically during pregnancy \[[@pone.0199041.ref095]\]. However, the variability of the microbiota during pregnancy remains unknown and a recent longitudinal study by DiGiulio et al. \[[@pone.0199041.ref096]\] found that the microbiotas of pregnant women are stable across time.

Lorenzo-Zuniga et al. \[[@pone.0199041.ref069]\] used a measure of gastrointestinal-specific anxiety---the Visceral Sensitivity Index (VSI) \[[@pone.0199041.ref097]\]---in adults with irritable bowel syndrome (IBS). While the VSI does assess general anxiety, as evidenced by its strong convergent validity with other measures of general anxiety, it also captures anxiety specific to gastrointestinal (GI) symptom severity \[[@pone.0199041.ref097], [@pone.0199041.ref098]\]. Given this finding, it may be that probiotics are more effective at alleviating GI-specific anxiety than general anxiety, at least in individuals with abnormal GI functioning. Probiotics specifically interact with the GI tract and appear to be well-suited for the treatment of GI distress. Indeed, a recent systematic review and meta-analysis has found that probiotics successfully reduce GI symptom severity in individuals with IBS while improving the integrity of the intestinal barrier \[[@pone.0199041.ref020]\]. However, it may be that probiotic-induced reductions in GI-specific anxiety are attributable to a reduction in GI symptoms, as Lorenzo-Zuniga et al. \[[@pone.0199041.ref069]\] found that GI-related quality of life improved prior to GI-specific anxiety. Another possibility is that probiotics are more effective at reducing anxiety in individuals with GI dysfunction, due to the presence of a more impaired microbiota; however, the other three clinical studies in this analysis that selected subjects with IBS found that probiotics had no effect on general anxiety \[[@pone.0199041.ref070], [@pone.0199041.ref072], [@pone.0199041.ref074]\].

Limitations {#sec024}
-----------

One important limitation of this study was the substantial heterogeneity present among both preclinical and clinical studies reviewed. Subject characteristics, outcome measures, probiotic strain (including single versus multispecies preparations), probiotic dose, and probiotic duration all varied substantially from study to study, and such variation likely contributed to the observed high level of statistical heterogeneity, which is problematic as high heterogeneity reduces the predictive validity of meta-analyses \[[@pone.0199041.ref099]\]. Although the use of random-effects models, as done here, can help to account for such heterogeneity \[[@pone.0199041.ref099]\], appropriate caution still needs to be taken when interpreting the present results, as they may not accurately reflect the true effect of probiotics.

Another limitation was that only 14 studies were included in the clinical meta-analysis, due to a lack of relevant research attributable to the novelty of using probiotics as a psychotropic intervention. The presence of more human trials could provide greater insight into the anxiolytic potential of probiotics and would also allow for more nuanced subgroup analyses. Additional preclinical research is similarly needed, as each preclinical subgroup analysis often encompassed only a handful of relevant standardized mean differences. A third limitation is that preclinical sample sizes (typically ranging from 10--40 animals) tended to be much smaller than those found in clinical studies. Although publication bias---a major concern when it comes to small sample size---was not observed among the included preclinical studies, small sample sizes may exacerbate other biases that can negatively affect the reliability and validity of study outcomes \[[@pone.0199041.ref100]\]. This may help explain the differential impact of probiotics observed in preclinical and clinical studies.

Conclusion {#sec025}
----------

While probiotic administration reduces anxiety-like behavior in rodents, the current state of clinical research does not (yet) support probiotics as an efficacious treatment for anxiety. *Lactobacillus rhamnosus* was nonetheless identified as a candidate anxiolytic probiotic species by both preclinical and clinical studies. An important target of future clinical investigation is the examination of the impact of probiotics on clinically significant anxiety, as probiotics only significantly reduced anxiety-like behavior in diseased rodents. It may also be worthwhile to investigate both higher dosages and longer durations of probiotic administration, as well as the effect of probiotics on specific subtypes of anxiety, such as anxiety related to gastrointestinal distress.
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